DOCSLIB.ORG

Diabetics Could Boost Daiichi's Nascent Heart Asset

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diabetics Could Boost Daiichi's Nascent Heart Asset September 26, 2017 Diabetics could boost Daiichi's nascent heart asset Amy Brown Daiichi Sankyo has revealed a phase III win with esaxerenone in hypertension, a project that many years ago emerged from the labs of Exelixis. If all goes well the asset could develop into a helpful revenue generator for both groups – the Japanese giant is struggling with patent expiries, and the US developer is in the midst of launching its oncology franchise. Esaxerenone works in a similar way to Pfizer’s long-expired Inspra, although presumably it has some pharmacological advantages – the pivotal trial pitted the two agents head to head. At the same time Daiichi announced a move into diabetic nephropathy, where Bayer is already active with another similar compound, and representing an area that arguably holds greater commercial potential. That Bayer project is finerenone, which like esaxerenone prevents binding of aldosterone by blocking the mineralocorticoid receptor and helping to control a rise in blood pressure. Like other next-generation antagonists in development it is described as non-steroidal, and has been designed for greater selectivity towards the mineralocorticoid receptor than Inspra plus stronger binding affinity. As such, it is hoped that these newer agents will be more tolerable than earlier compounds like eplerenone, Inspra's active ingredient. Fear of hyperkalaemia, caused by very high potassium levels, has severely restricted the use of Inspra, despite evidence that the drug can reduce mortality and morbidity in patients with heart failure. That potential remains to be proven, however, and limited detail released by Daiichi on the Esax-HTN study leaves the question unanswered for now. The trial recruited 1,000 Japanese patients with hypertension and dosed them with one of two doses of esaxerenone or Inspra, measuring blood pressure change from baseline as the primary endpoint. The company said the primary endpoint had been achieved, with no significant safety concerns. Targeting the mineralocorticoid receptor Product Company Notes Inspra (eplerenone) Pfizer Launched in 2003; sales peaked at $233m in 2013. Aldactone Active ingredient first launched in 1961; sales of Aldactone peaked at Pharmacia (spironolactone) $224m. Finerenone Bayer Currently in phase III. CS-3150 (esaxerenone) Daiichi Sankyo Currently in phase III. Mitsubishi MT-3995 Only in active development for Nash, in phase II. Tanabe LY2623091 Eli Lilly Presumed abandoned in 2015 in phase II. PF‐03882845 Pfizer Presumed abandoned in 2013 in phase I. Source: EvaluatePharma The incidence of hyperkalaemia will be crucial to determining the potential of esaxerenone, assuming that it is also at least as effective at controlling blood pressure as Inspra. Bayer’s work with finerenone has also so far failed to prove its agent’s benefits over Inspra, although signals of greater potential can possibly be found in a large phase IIb study presented in 2015. Arts-HF, in patients hospitalised for worsening heart failure, found no difference between finerenone and Inspra on the primary endpoint, change in a measure of cardiac stress. Secondary endpoints pointed to a numerical benefit for the Bayer project on measures such as the incidence of death or cardiovascular hospitalisation. The trial, which was criticised at the time for being underpowered, was not designed for statistical analysis on the secondary endpoints, while rates of hyperkalaemia were similar between the two arms. Still, this did not stop Bayer from proclaiming a move into a large pivotal finerenone programme, comprising three studies – two in diabetic nephropathy and one in chronic heart failure - although the latter indication was dropped in 2016. Any bigger? With nothing available to specifically treat nephropathy, and growing rates of diabetes, this is arguably a more attractive area for these agents anyway - around 40% of diabetics are estimated to suffer kidney damage. It is hoped that this mechansim will promote an improvement in kidney function; aldosterone, which is active in the nephrons, is considered a potent mediator of organ damage. Bayer’s two huge kidney disease studies, which are seeking to recruit 11,200 patients, should provide an answer, though data are unlikely to emerge before 2020. And it should be remembered that there have been several dropouts from this space: despite running fairly recent trials Mitsubishi Tanabe does not seem to be pushing on with its MRA antagonist MT-3995 in diabetes patients, while Pfizer canned PF‐03882845 about five years ago. In the meantime Morgan Stanley analysts reckon Daiichi could build esaxerenone to a ¥10-20bn ($89-179m) franchise in Japan, but that development costs are likely to curtail international ambitions. Strong signals in diabetes patients could prompt the company to think bigger. Late stage diabetic nephropathy pipeline (novel agents) Product Company Pharma class Trials Data Endothelin A receptor Atrasentan AbbVie Sonar: NCT01858532 2018 antagonist Mineralocorticoid receptor Fidelio-DKD: NCT02540993; Figaro- Finerenone Bayer 2019/2020 antagonist DKD: NCT02545049 Johnson Invokana SGLT 2 inhibitor Credence: NCT02065791 2019 & Johnson Farxiga AstraZeneca SGLT 2 inhibitor Dapa-CKD: NCT03036150 2020 Esaxerenone Daiichi Mineralocorticoid Exas-DN: JapicCTI-173695 2019? (CS-3150) Sankyo receptor antagonist This story has been corrected to state that Bayer has dropped development of finerenone in heart failure. To contact the writer of this story email Amy Brown in London at [email protected] or follow @ByAmyBrown on Twitter More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
    Kidney360 Publish Ahead of Print, published on July 23, 2020 as doi:10.34067/KID.0000922020 Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm Michael R Lattanzio(1), Matthew R Weir(2) (1) Division of Nephrology, Department of Medicine, The Chester County Hospital/University of Pennsylvania Health System (2) Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD Correspondence: Matthew R Weir University of Maryland Medical Center Division of Nephrology 22 S. Greene St. Room N3W143 Baltimore, Maryland 21201 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abbreviations PA=Primary Hyperaldosteronism CVD=Cardiovascular Disease PAPY=Primary Aldosteronism Prevalence in Hypertension APA=Aldosterone-Producing Adenoma BAH=Bilateral Adrenal Hyperplasia ARR=Aldosterone Renin Ratio AF=Atrial Fibrillation OSA=Obstructive Sleep Apnea OR=Odds Ratio AHI=Apnea Hypopnea Index ABP=Ambulatory Blood Pressure AVS=Adrenal Vein Sampling CT=Computerized Tomography MRI=Magnetic Resonance Imaging SIT=Sodium Infusion Test FST=Fludrocortisone Suppression Test CCT=Captopril Challenge Test PAC=Plasma Aldosterone Concentration PRA=Plasma Renin Activity MRA=Mineralocorticoid Receptor Antagonist MR=Mineralocorticoid Receptor 2 Abstract Nearly seven decades have elapsed since the clinical and biochemical features of Primary Hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly since an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Mineralocorticoid Receptor Blockers for Moderate Kidney Dysfunction: More Merit Than Ever?
    Hypertension Research (2021) 44:1352–1354 https://doi.org/10.1038/s41440-021-00690-6 COMMENT Mineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever? 1 1 1 Masashi Mukoyama ● Takashige Kuwabara ● Masataka Adachi Received: 28 May 2021 / Accepted: 31 May 2021 / Published online: 15 July 2021 © The Japanese Society of Hypertension 2021 Mineralocorticoid receptor (MR) antagonists, such as spir- MR activity with high specificity. To date, several clinical onolactone and eplerenone, are currently used to treat studies have been performed to evaluate its effects [4–6], hypertension and chronic heart failure. MR antagonists act which revealed effective blood pressure reduction with rela- on MRs expressed in the distal tubules of the kidney, tively few adverse events, including hyperkalemia (Table 1). including distal convoluted tubules, connecting tubules and In addition, esaxerenone can further reduce urinary albumin the cortical collecting duct, thereby promoting sodium excretion in addition to RAS inhibitors without significantly excretion without the loss of potassium into the urine [1]. affecting renal function [6]. Finerenone, a second nonsteroidal MR antagonists may be effective for the treatment of low- MR blocker for which large-scale clinical trials have been 1234567890();,: 1234567890();,: renin hypertension and are preferentially used for the completed [7, 8], showed a lower risk of CKD progression treatment of primary aldosteronism; furthermore, in patients and cardiovascular events than placebo in patients with CKD with resistant hypertension, additional administration at a and type 2 diabetes (Table 1). Based on these results, much low to moderate dose (spironolactone, 25–50 mg/day) may attention has been given to novel MR blockers as promising further decrease blood pressure [2].
    [Show full text]
  • The Role of Aldosterone Inhibitors on Cardiac Ischemia/Reperfusion Injury
    Canadian Journal of Physiology and Pharmacology THE ROLE OF ALDOSTERONE INHIBITORS ON CARDIAC ISCHEMIA/REPERFUSION INJURY Journal: Canadian Journal of Physiology and Pharmacology Manuscript ID cjpp-2020-0276.R1 Manuscript Type: Review Date Submitted by the 16-Jul-2020 Author: Complete List of Authors: Dragasevic, Nevena; University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia JAKOVLJEVIC, Vladimir; University of Kragujevac, Faculty of Medical Sciences, DepartmentDraft of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia, Department of Physiology; 1st Moscow State Medical University IM Sechenov, Moscow, Russian Federation, Department of Human Pathology Zivkovic, Vladimir; University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Draginic, Nevena; University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Andjic, Marijana; University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Svetozara Markovica 69, 34 000 Kragujevac, Serbia Bolevich, Sergey; University IM Sechenov, 1st Moscow State Medical,Trubetskaya street 8, 119991 Moscow, Department of Human Pathology Jovic, Slavoljub; University of Belgrade, Department of Physiology and Biochemistry, Faculty of Veterinary Medicine, Bul. Oslobodjenja 18, Belgrade, Serbia Is the invited manuscript for consideration in a Special Joint North American/European
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Report on the Deliberation Results December 4, 2018 Pharmaceutical
    Report on the Deliberation Results December 4, 2018 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Minnebro Tablets 1.25 mg Minnebro Tablets 2.5 mg Minnebro Tablets 5 mg Non-proprietary Name Esaxerenone (JAN*) Applicant Daiichi Sankyo Company, Limited Date of Application February 26, 2018 Results of Deliberation In its meeting held on December 3, 2018, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product. The re-examination period is 8 years. Neither the drug product nor its drug substance is classified as a poisonous drug or a powerful drug. Condition of Approval The applicant is required to develop and appropriately implement a risk management plan. *Japanese Accepted Name (modified INN) This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Review Report November 12, 2018 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency (PMDA). Brand Name Minnebro Tablets 1.25 mg Minnebro Tablets 2.5 mg Minnebro Tablets 5 mg Non-proprietary Name Esaxerenone Applicant Daiichi Sankyo Company, Limited Date of Application February 26, 2018 Dosage Form/Strength Each tablet contains 1.25 mg, 2.5 mg, or 5 mg of Esaxerenone.
    [Show full text]
  • Esaxerenone: First Global Approval
    Drugs https://doi.org/10.1007/s40265-019-01073-5 ADISINSIGHT REPORT Esaxerenone: First Global Approval Sean Duggan1 © Springer Nature Switzerland AG 2019 Abstract Esaxerenone (MINNEBRO™)—a novel oral, non-steroidal, selective mineralocorticoid receptor blocker—is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this frst global approval for the treatment of hypertension. 1 Introduction 1.1 Company Agreements Daiichi Sankyo are developing esaxerenone (MINNE- In March 2006, Sankyo Co., Ltd, a subsidiary of Daiichi BRO™), a novel oral, non-steroidal, selective mineralocor- Sankyo, entered into a research collaboration agreement ticoid receptor blocker, for the treatment of hypertension and with Exelixis Inc. to develop and commercialise novel ther- diabetic nephropathies. Excessive mineralocorticoid recep- apies targeting the mineralocorticoid receptor [7]. Daiichi tor activation by endogenous ligands such as aldosterone has Sankyo obtained an exclusive, worldwide licence to certain been shown to play an important role in the development of intellectual property primarily relating to compounds that hypertension, as well as progression of nephropathy and car- modulate the mineralocorticoid receptor, including esaxer- diovascular disease [1–4]. Esaxerenone is thought to exert an enone [7, 8]. After completion of the research term, Sankyo antihypertensive efect by blocking mineralocorticoid recep- Co., Ltd has assumed responsibility for all further clinical tor activation. Esaxerenone was approved in Japan for the and regulatory development of the drug.
    [Show full text]
  • Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
    biomedicines Article Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker Wei-Ting Chang 1,2,3 and Sheng-Nan Wu 4,5,* 1 Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan; [email protected] 2 Division of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan 71004, Taiwan 3 Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan 4 Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan 5 Institute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan 70101, Taiwan * Correspondence: [email protected]; Tel.: +886-6-2353535 (ext. 5334); Fax: +886-6-2362780 Abstract: Esaxerenone (ESAX; CS-3150, Minnebro®) is known to be a newly non-steroidal min- eralocorticoid receptor (MR) antagonist. However, its modulatory actions on different types of ionic currents in electrically excitable cells remain largely unanswered. The present investigations were undertaken to explore the possible perturbations of ESAX on the transient, late and persistent + components of voltage-gated Na current (INa) identified from pituitary GH3 or MMQ cells. GH3- cell exposure to ESAX depressed the transient and late components of INa with varying potencies. The IC50 value of ESAX required for its differential reduction in peak or late INa in GH3 cells was Citation: Chang, W.-T.; Wu, S.-N. estimated to be 13.2 or 3.2 µM, respectively. The steady-state activation curve of peak INa remained Characterization of Direct unchanged during exposure to ESAX; however, recovery of peak INa block was prolonged in the Perturbations on Voltage-Gated presence 3 µM ESAX.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2017
    Daiichi Sankyo Group Value Report 2017 Daiichi Sankyo Group Value Daiichi Sankyo Group Value Report 2017 Contents Messages from the CEO & the COO 02 Highlights of Value Report 2017 Our Mission 06 Daiichi Sankyo’s Strengths 08 Major Accomplishments in Fiscal 2016 10 Daiichi Sankyo’s Value Creation Process 12 5-Year Business Plan (FY2016 - FY2020) History of Daiichi Sankyo 14 Transformation 2025 Vision and 5-Year Business Plan 18 DS — A Bridge to Tomorrow 2025 Vision 20 5-Year Business Plan and its Progress 21 Operations and Financial Position 48 The Daiichi Sankyo Group’s Value Chain and Organization 52 P02-05 P08-09 P21-47 Global Management Structure 54 Business Activities Messages from the CEO & Daiichi Sankyo’s Strengths 5-Year Business Plan and the COO its Progress Business Units Here, you will find messages from This section explains the Daiichi Sankyo This section looks at the strategic targets ・ Sales & Marketing Unit 56 Chairman and CEO George Nakayama Group’s unique strengths, namely Science set forth for accomplishing the goals of the ・ Sales & Marketing Unit: Daiichi Sankyo Espha Co., Ltd. 57 on the management practices that take & Technology, Global Organization & 5-year business plan, progress toward advantage of the Group’s strengths and Talent, and Presence in Japan. these targets, and the initiatives that will ・ Vaccine Business Unit 58 from President and COO Sunao Manabe on be implemented in the future. ・ Daiichi Sankyo Healthcare Co., Ltd. 59 the Group’s initiatives for accomplishing the goals of the 5-year business plan. ・ Daiichi Sankyo, Inc.（DSAC） 60 ・ Luitpold Pharmaceuticals, Inc.
    [Show full text]
  • The 2020 Italian Society of Arterial Hypertension (SIIA) Practical Guidelines for the Management of Primary Aldosteronism
    International Journal of Cardiology Hypertension 5 (2020) 100029 Contents lists available at ScienceDirect International Journal of Cardiology Hypertension journal homepage: www.journals.elsevier.com/international-journal-of-cardiology-hypertension/ Review Article The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism Gian Paolo Rossi a,*, Valeria Bisogni a, Alessandra Violet Bacca b, Anna Belfiore c, Maurizio Cesari a, Antonio Concistre d, Rita Del Pinto e, Bruno Fabris f, Francesco Fallo g, Cristiano Fava h, Claudio Ferri e, Gilberta Giacchetti i, Guido Grassi j, Claudio Letizia d, Mauro Maccario k, Francesca Mallamaci l, Giuseppe Maiolino a, Dario Manfellotto m, Pietro Minuz h, Silvia Monticone n, Alberto Morganti o, Maria Lorenza Muiesan p, Paolo Mulatero n, Aurelio Negro q, Gianfranco Parati r, Martino F. Pengo r, Luigi Petramala d, Francesca Pizzolo h, Damiano Rizzoni p, Giacomo Rossitto a,s, Franco Veglio n, Teresa Maria Seccia a a Clinica dell'Ipertensione Arteriosa, Department of Medicine - DIMED, University of Padua, Italy b Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy c Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy d Department of Translational and Precision Medicine, Unit of Secondary Arterial Hypertension, "Sapienza" University of Rome, Italy e University of L'Aquila, Department of Life, Health and Environmental Sciences, San Salvatore Hospital, L'Aquila, Italy f Department of Medical Sciences, Universita degli Studi di Trieste, Cattinara Teaching Hospital, Trieste, Italy g Department of Medicine, DIMED, Internal Medicine 3, University of Padua, Italy h Department of Medicine, University of Verona, Policlinico "G.B.
    [Show full text]
  • Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    pharmaceuticals Review Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease Nina Vodošek Hojs 1,* , Sebastjan Bevc 1,2, Robert Ekart 2,3 , Nejc Piko 3 , Tadej Petreski 1,2 and Radovan Hojs 1,2 1 Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; [email protected] (S.B.); [email protected] (T.P.); [email protected] (R.H.) 2 Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia; [email protected] 3 Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-366-133; Fax: +386-2-321-28-45 Abstract: Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore, prevention and treatment of DKD are of utmost importance. Much research has been dedicated to the optimization of DKD treatment. In the last few years, mineralocorticoid receptor antagonists (MRA) have experienced a renaissance in this field with the development of non-steroidal MRA. Steroidal MRA have known cardiorenal benefits, but their use is limited by side effects, especially hyperkalemia. Non-steroidal MRA still block the damaging effects of mineralocorticoid receptor overactivation (extracellular fluid volume expansion, inflammation, fibrosis), but with fewer side effects (hormonal, hyperkalemia) Citation: Vodošek Hojs, N.; Bevc, S.; than steroidal MRA. This review article summarizes the current knowledge and newer research Ekart, R.; Piko, N.; Petreski, T.; Hojs, conducted on MRA in DKD.
    [Show full text]
  • The Role of Spironolactone in Patients With
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 18 May 2021 doi:10.20944/preprints202105.0414.v1 WHEN OFF TARGET EFFECTS ARE ON TARGET: THE ROLE OF SPIRONOLACTONE IN PATIENTS WITH COVID-19 Christopher Wilcox, MD PhD 1, Bertram Pitt, MD 2 1 Division of Nephrology and Hypertension Center, Georgetown University, Washington DC 20007 2 Division of Cardiology, University of Michigan, Ann Arbor, MI 48109 Short Title: Spironolactone off target effects Address for correspondence: Christopher Wilcox, MD, PhD Georgetown University Department of Nephrology and Hypertension 3800 Reservoir Road, NW PHC F6003 Washington, DC 20007 Fax: 877-625-1483 Email: [email protected] 1 © 2021 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 18 May 2021 doi:10.20944/preprints202105.0414.v1 ABSTRACT Aims: Spironolactone is a steroidal mineralocoricosteroid receptor antagonist (MRA) used for treatment of resistant hypertension, heart failure and edema. It exerts class specific adverse effects that are shared by other MRAs. Additionally, it exerts unique “off target” steroidal effects that include gynecomastia, impotence and loss of libido in males and menstrual irregularity in females. Together, these have led to a poor tolerability and limited use despite positive results in many randomized, controlled clinical trials. We review the off-target effects of spironolactone that may summate with its MRA action to provide an advantageous profile for prevention or treatment of patients with COVID-19. Methods: Literature review using PubMed Central. Results: The blockade by spironolactone of the androgen receptor should diminish the expression of transmembrane protease serine 2 (TMPRSS2) that has an androgen promoter while its MRA action should enhance the expression of protease nexin1 (PN1) that inhibits furin and plasmin.
    [Show full text]